A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
Public ClinicalTrials.gov record NCT02951182. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group, multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and triple combination with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF).
Study identification
- NCT ID
- NCT02951182
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2016 (Actual)
- Primary completion
- Aug 2017 (Actual)
- Completion
- Aug 2017 (Actual)
- Last update posted
- Aug 28, 2020
2016 – 2017
United States locations
- U.S. sites
- 22
- U.S. states
- 17
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Arizona Board of Regents on behalf of the University of Arizona | Tucson | Arizona | — | — |
| Stanford University | Palo Alto | California | — | — |
| University of California | San Francisco | California | — | — |
| National Jewish Health | Denver | Colorado | — | — |
| Joe Di Maggio Cystic Fibrosis & Pulmonary Center | Hollywood | Florida | — | — |
| Central Florida Pulmonary Group | Orlando | Florida | — | — |
| St. Luke's CF Center of Idaho | Boise | Idaho | — | — |
| Cystic Fibrosis Center of Chicago | Glenview | Illinois | — | — |
| The Johns Hopkins Hospital | Baltimore | Maryland | — | — |
| Boston Children's Hospital | Boston | Massachusetts | — | — |
| Massachusetts General Hospital Cystic Fibrosis Center | Boston | Massachusetts | — | — |
| University of Minnesota | Minneapolis | Minnesota | — | — |
| New York Medical College | Hawthorne | New York | — | — |
| Long Island Jewish Medical Center | New Hyde Park | New York | — | — |
| Columbia University Medical Center | New York | New York | — | — |
| Nationwide Children's Hospital | Columbus | Ohio | — | — |
| Respiratory Diseases of Children and Adolescents | Oklahoma City | Oklahoma | — | — |
| UPMC OSPARS Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | — | — |
| Sanford Children's Specialty Clinic Sanford Research USD | Sioux Falls | South Dakota | — | — |
| The University of Texas Southwestern Center | Dallas | Texas | — | — |
| Children's Hospital of the Kings Daughters | Norfolk | Virginia | — | — |
| Seattle Children's Hospital | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02951182, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2020 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02951182 live on ClinicalTrials.gov.